Please login to the form below

Not currently logged in
Email:
Password:

ASCO 2013

This page shows the latest ASCO 2013 news and features for those working in and with pharma, biotech and healthcare.

Have you got the adaptability factor?

Have you got the adaptability factor?

that at ASCO 2013, Tweets were up 300 per cent on 2011, #ASCO13 was trending worldwide and over 16, 000 tweets were posted – using said hash tag – by a mixture of ... founder of Big Eye Dear. 1st August 2013.

Latest news

  • ASCO: Boehringer's nintedanib boosts survival in lung cancer subset ASCO: Boehringer's nintedanib boosts survival in lung cancer subset

    ASCO: Boehringer's nintedanib boosts survival in lung cancer subset. Trial date demonstrates benefit in NSCLC patients with adenocarcinomas. ... Germany, who was the principal investigator in the trial and presented the data at ASCO.

  • ASCO: Amgen says viral therapy for melanoma ASCO: Amgen says viral therapy for melanoma "encouraging"

    ASCO: Amgen says viral therapy for melanoma "encouraging". T-VEC is potential advancement in skin cancer treatment. ... The results of the OPTiM study – reported at the American Society of Clinical Oncology (ASCO) meeting in Chicago – are a milestone

  • ASCO: Merck and BMS trumpet melanoma trials ASCO: Merck and BMS trumpet melanoma trials

    ASCO: Merck and BMS trumpet melanoma trials. Positive study results for anti-PD-1 candidates lambrolizumab and nivolumab. ... Merck &Co and Bristol-Myers Squibb (BMS) both presented positive phase III data for their anti-PD-1 melanoma candidates at the

  • Late-stage failure for Merck’s cilengitide in brain cancer Late-stage failure for Merck’s cilengitide in brain cancer

    Merck said detailed trial results will be submitted for presentation at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting and publication in a peer-reviewed journal. ... 25th February 2013.

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics